The Red Queen’s Gambit: Helping the Lab Avoid Burnout

In Lewis Carroll’s book Through the Looking Glass, Alice is being given a tour of Looking-Glass Land by the Red Queen when this happens:

Alice never could quite make out, in thinking it over afterwards, how it was that they began: all she remembers is, that they were running hand in hand, and the Queen went so fast that it was all she could do to keep up with her: and still the Queen kept crying “Faster! Faster!” but Alice felt she could not go faster, though she had not breath left to say so.

However, after running until Alice feels absolutely exhausted she looks around in surprise to find that they are exactly in the same place where they had begun.

Carroll, Lewis (1991) [1871]. “2: The Garden of Live Flowers”. Through the Looking-Glass (The Millennium Fulcrum Edition 1.7 ed.). Project Gutenberg.

“Well, in our country,” said Alice, still panting a little, “you’d generally get to somewhere else—if you ran very fast for a long time, as we’ve been doing.”

“A slow sort of country!” said the Queen. “Now, here, you see, it takes all the running you can do, to keep in the same place. If you want to get somewhere else, you must run at least twice as fast as that!”

Laboratory medicine is one of many areas of healthcare where more is constantly expected to be done with less, where the inhabitants of our looking-glass land have to run as fast as we can just to maintain the status quo. Also like many areas of medicine, our already strained workforce suddenly became victims of an unprecedented global COVID-19 pandemic stressing and stretching our capabilities. The gamble then, is expecting members of our incredible laboratory medicine community to run so fast that they ultimately burn themselves out.

From the December 2020 New York Times article on laboratory workers in the time of COVID-19 titled, “‘Nobody Sees Us’: Testing-Lab Workers Strain Under Demand“:

Morale in the labs has flagged as the country continues to shatter records for caseloads, hospitalizations and deaths. The nation’s testing experts know these statistics better than anyone: They count the numbers themselves, sample by sample. But they are also easy targets of criticism and complaint.

“There is always this undercurrent of, it’s never good enough,” said Dr. Abbott, of Deaconess Hospital in Indiana. “It’s devastating. We’re working as hard as we can.”

In April 2020, just a few weeks after COVID-19 was officially declared a global pandemic, the April issue American Journal of Clinical Pathology opened with two timely editorials, one from Dr. Jeanette Guarner discussing the three emergent coronavirus diseases of the past two decades (SARS, MERS and COVID-19) and the next by Dr. Steven H Kroft titled “Well-Being, Burnout, and the Clinical Laboratory.”

In this issue were three different articles, the results of extensive surveys conducted by the ASCP to determine the job satisfaction, well-being and burnout prevalent among 1) pathologists, 2) pathology residents and fellows, and 3) laboratory professionals. Knowing now what clinical laboratories, leaders and trainees were about to go through thanks to COVID-19, made these publications about the stress and satisfaction felt by those in lab medicine was timely (if not grimly ironic).

What is shown in those excellent publications, and what we can only assume has become more true, is “burnout,” (the “combination of emotional exhaustion, depersonalization, and loss of sense of personal accomplishment”) prevalent in laboratory medicine, with the majority of pathologists, residents and fellows, and professionals reporting having experienced it if not experiencing it as an ongoing problem.

There is no single solution to burnout in the laboratory. As Dr. Kroft outlines in his editorial, these surveys can be seen as initial steps to understanding the problem and plotting potential courses forward (“a roadmap for what workplace landmines to try to avoid.”). But several meaningful pieces of data emerged from these surveys as well: Overwhelmingly, pathologists and lab professionals enjoy their work (91% and 86%) and feel valued by their colleagues (79% and 71%). Also telling is the fact that while well over 90% of laboratory professionals reported “a little bit of stress” to “a lot of stress,” 2/3rds of them reported feeling either “somewhat satisfied” or “very satisfied” with their jobs. Clearly, no one knows the value of laboratory medicine better than those of us doing it. But recognition and support coming from within the laboratory space should be seen as a good first step to acknowledging these contributions.

Recognition is needed from outside lab leadership as well, and especially should be accompanied by both stress-reducing measures (filling labor gaps, adequate compensation and benefits etc.) and opportunities to feel ownership and personal investment in the contributions we make to healthcare. Healthcare leaders, professional organizations, and all of those who were vocal supporters of labs’ contributions during the worst of the pandemic, should continue to advocate on behalf of laboratory staff’s well-being.

Even as vaccines and other mitigation efforts are providing more widespread pandemic relief in the United States, it’s clear that we are now through a COVID-19 looking glass. The lab was already running as fast as it could, but to get us to where we are now, many of us started running twice as fast. Hopefully we will both continue to run and also be supported in that ongoing race to stay where we are.

-Dr. Richard Davis, PhD, D(ABMM), MLS(ASCP)CM is a clinical microbiologist and regional director of microbiology for Providence Health Care in Eastern Washington. A certified medical laboratory scientist, he received his PhD studying the tropical parasite Leishmania. He transitioned back to laboratory medicine (though he still loves parasites!), and completed a clinical microbiology fellowship at the University of Utah/ARUP Laboratories in Utah before accepting his current position. He is a 2020 ASCP 40 Under Forty Honoree.

TRANSforming Healthcare: The Role of The Laboratory

In 2006, an international group of human rights experts assembled in Yogyakarta, Indonesia to address patterns of discrimination and abuse of individuals related to sexual orientation and gender identity. This document, The Yogyakarta Principles: Principles on the application of

international human rights law in relation to sexual orientation and gender identity, has been widely accepted as setting the standards for fundamental human rights for all, with specific attention to sexual orientation and gender identify. It is worth studying, as it articulates rights in many domains of everyday life. Of direct relevance to our Profession are Principle #12, The Right to Work; Principle number #17, The Right to the Highest Attainable Standard of Health; and Principle #18, Protection from Medical Abuses.1  It is the goal to “Adopt the policies, and programmes of education and training, necessary to enable persons working in the healthcare sector to deliver the highest attainable standard of healthcare to all persons, with full respect for each person’s sexual orientation and gender identity.”

Because the medical laboratory provides critical data for patient management, laboratory professionals and pathologists must be able to evaluate laboratory and biopsy results wisely and appropriately.  Yet we often lack fundamental and essential information necessary to support optimal and personalized care for patients on cross-sex hormones.

The number of individuals who self-identify as transgender has risen significantly in the past decade. Transgender people face discrimination, harassment, abuse, and denial of legal rights. They often feel unsafe, and a high proportion face bullying at school or at work. The Centers for Disease Control (CDC) estimates that about 2% of high school students in the U.S. identify as transgender; among them, 35% attempt suicide. Transgender adults are twice as likely of being homeless, four times more likely to live in poverty, four times as likely as being HIV-infected, and twice as likely to be unemployed compared to the general population.2 Individuals without access to appropriate care may purchase hormones from unreliable sources, so that the dose, drug contents, and potential side-effects are poorly controlled or even toxic.

Healthcare systems often fail the transgender community. First, given the high rate of poverty, unemployment, and homelessness, access to basic health services is not available for many individuals. Second, even in those healthcare institutions that serve the uninsured, appropriate services are often lacking, including the absence of knowledgeable providers and the lack of cultural competency in the institution. The few academic hospitals with services and clinics oriented to serving transgender patients struggle to provide optimal care, because there are important gaps in knowledge regarding how best to care for transgender patients. Many health care clinics and professionals lack training in asking all patients “What pronouns do you prefer to use in referring to yourself?” This is a straightforward way to acknowledge gender diversity and sets the first stage of a potentially trusting relationship.


Examples abound regarding information gaps in managing patients on cross-sex hormones. For instance, there are only a handful of papers in the literature addressing care of elderly patients, and little is known about the risks or health benefits of long-term cross-sex hormone use. For children who elect to start puberty blockers so that their development in adolescence is more appropriate to their self-identified gender, long-term effects on bone health are poorly understood. A number of laboratory tests have different reference ranges for “men” and “women,” such as n-telopeptide as a marker of bone turnover. Most labs have not established appropriate reference ranges for patients on cross-sex hormones, nor are there good long-term studies to help guide management of bone health in this setting. And there may be times when the managing health care professionals do not realize that a patient is taking cross-sex hormones.

Patient identifiers are often incomplete. Many patients on cross-sex hormones have not had surgery to remove their gonads. Therefore, a trans-man can present to the Emergency Room with severe abdominal pain, but those managing his care may not suspect ovarian torsion, ectopic pregnancy, or other conditions of the fallopian tubes, ovaries, uterus, and cervix. Similarly, trans-women may have testes and prostates. Most patient registration systems lack the ability to record sex chromosomes and gender identity separately. Also, many individuals identify as non-binary; some are not taking cross-sex hormones at all. These factors affecting presentation are currently captured poorly. If at all, in the medical record but may have profound implications for care. Otherwise, implicit biases can adversely affect patient care.

Finally, we all have work to do to ensure that our patients and colleagues feel welcomed and respected in our labs, training programs, and hospitals. One important step is for each of us to gain self-awareness of our attitudes and biases, and to educate ourselves. A good starting place is Gupta’s article in Lab Medicine;3 another is the book Trans Bodies, Trans Selves by psychologist Laura Erickson-Schroth.4 Second, we must continue to foster inclusive workplaces, to stand up when we witness abuses or so-called “microagressions.” Third, we must work directly with patients to hear their concerns, and to provide the information needed regarding our lab results and pathology reports. We must respond to the gaps identified by our patients, do the research necessary to get better answers, and partner with other health care professionals to address the needs of our patients.

References

  1. The Yogyakarta Principles. 2017. https://yogyakartaprinciples.org/
  2. Meerwijk EL, Sevelius J. Transgender population size in the United States- a Meta-Regression of Population-Based Probability Samples. Am J Public Health 2017; 107(2):e1-e8. PMID 28075632
  3. Gupta S, Imborek KL, Kraswoski MD. Challenges in transgender healthcare: the pathology perspective. Lab Medicine 2016;47:3;180–188.
  4. Erickson-Schroth L. Trans Bodies, Trans Selves: A Resource for the Transgender Community. 2014, Oxford University Press.

-Dr. Upton is board certified in Anatomic Pathology and Cytology and directed an autopsy service and forensic pathology fellowship program at Beth Israel Deaconess Medical Center in Boston, Massachusetts. She has also practiced cytopathology and general surgical pathology, and has focused on genitourinary pathology, head and neck pathology, and gastroenterology (GI) and liver pathology. From 1982-85 and 1987-2002, Dr. Upton lived in Boston and taught at Tufts, Boston, and Harvard Universities. Since 2002, she has been at the University of Washington in Seattle, where she formerly directed the GI and Hepatic Pathology Service the Pathology Residency Program and the UW GI and Hepatic Pathology Fellowship. Currently Emeritus Professor of Pathology, she continues to practice Surgical Pathology, Autopsy Pathology, and Cytopathology, and she is one of the specialists at UW in the areas of GI, liver, and pancreatic pathology.

Hematology Case Study: Unusual Lymphocytes Seen in an Apparently Healthy Young Adult

A healthy 30 year old woman visited her primary care physician concerned about a rash with questionable infection on her hands. The physician prescribed an antibiotic for infection and ordered a CBC. From the results below, it can be seen that the patient had a pancytopenia and a relative lymphocytosis.

Table 1. CBC results.
Table 2. Automated differential results

A manual differential was performed on CellaVision and the presence of large, clefted lymphocytes with immature features was noted. A request for pathology review was sent to the pathologist. The pathologist’s review stated “ Atypical lymphocytosis, specimen to be submitted for flow cytometry. Report to follow. Occasional atypical lymphocytes with immature features also noted. Lymphocyte population is predominantly mature”

The peripheral blood sample was sent out for immunophenotyping by flow cytometry and FISH studies. Flow cytology reported “precursor B-cell population expressing CD19, CD10, HLA-DR, and CD34 is identified. Percent of abnormal cells, 30%. These findings are consistent with precursor B-lymphoblastic leukemia.” While we tend to associate a leukemia diagnosis with a high white blood cell count, and the presence of blasts, this patient was unusual in that she did not have a high WBC or blasts seen on the peripheral smear. Pancytopenia in ALL has been noted in literature. A study of new onset pancytopenia in adults showed that the majority of cases were acute myeloid leukemia, but ALL and other lymphomas also caused pancytopenia3. Another study noted that “pancytopenia followed by a period of spontaneous recovery may precede the diagnosis of acute lymphoblastic leukemia.”1 While the pathologist did not identify blasts on this differential, and cells were predominately mature, WBC was very low, and our analyzer did flag “?blasts/abnormal lymphs” and reflexed the manual differential.

Image 1. Clefted lymphocytes seen on peripheral smear.
Image 2. Clefted lymphocytes on CellaVision.
Table 3. FISH report.

Leukemia is a broad term that includes a number of different chronic and acute diagnoses. Chronic and acute forms are further broken down into myeloid and lymphoid and then into subtypes. The French-American-British (FAB) classification of acute leukemias was devised in the 1970’s and 1980’s and was based on cytochemical staining and morphology of cells. These tests were performed manually and relied on what the cells look like under the microscope. The series of stains were used to differentiate myeloblasts from lymphoblasts. I’m old enough that I remember learning about these stains when they were being developed and thinking how amazing they were!

We’ve come a long way since the early 1980’s! Although the FAB diagnostic criteria are not entirely forgotten, the World Health Association (WHO) classification, first published in 2001, has largely replaced the FAB classification. The newest guidelines for Acute Lymphoblastic Leukemias (ALL) were published by WHO in 2016. These new guidelines supplement morphology and cytochemical staining with newer testing which can now identify and distinguish B cell and T cell ALL. In making a diagnosis, peripheral blood and/or bone marrow aspirate samples are subject to flow cytometry immunophenotyping and chromosome testing such as cytogenics or fluorescence in situ hybridization(FISH). Molecular tests can also be done to look for specific gene changes in the leukemia cells. The WHO classification has become preferred because these new tests can give more information that is important for treatment. Prognosis for ALL depends on patient age, WBC counts at diagnosis and these specific test results which tell us which subtype of ALL is present. The presence and identification of chromosomal alterations is important for diagnosis and therapy decisions. Identifying chromosomal alterations can also lead to better risk classification which is significant because of the knowledge that, while rearrangements tend to have poorer outcomes, some rearrangements actually offer a better prognosis. With the future era of individualized, targeted therapy for leukemia, combining conventional cytogenics with molecular and FISH methods will greatly enhance the accuracy of information and provide patients with more specific and customized treatment options.

While ALL is the most common childhood leukemia, it is not as commonly seen in adults. B cell ALL is more common than T cell ALL in all ages, and accounts for about 90% of ALL cases in children and about 75% of ALL cases in adults. Cure rates in children exceed 90% but in adults varies with age and depending on chromosomal alterations. Most B cell ALL subtypes with chromosome translocations tend to have a poorer outcome than those without translocations. As well, younger adults, <50 years old, have better prognosis than older adults.

This patient did not have a BCR/ABL rearrangement or MLL gene locus 11q23 translocation, which both carry poorer prognoses, but she also did not have a translocation between chromosome 12 and 21 or more than 50 chromosomes, both of which offer more favorable prognoses. This young woman therefore would be in an average risk category and appears to have been diagnosed very early in the course of her disease. We have not seen any further workup, as the patient is being treated at another facility. We wish her well in her leukemia treatments.

References

  1. Hasle H, Heim S, Schroeder H, et al. Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL). Leukemia. 1995 Apr;9(4):605-608.
  2. Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol. 2017 Mar 20;35(9):975-983. doi: 10.1200/JCO.2016.70.7836. Epub 2017 Feb 13. PMID: 28297628; PMCID: PMC5455679
  3. Bone Marrow evaluation in new onset pancytopenia. Human Pathology. Vol 44, Issue 6. June 2013
  4. Hematology: Basic Principles and Practice, 7th Edition. Ronald Hoffman, Edward J. Benz, et al. 2018 Elsevier
Socha-small

-Becky Socha, MS, MLS(ASCP)CMBBCM graduated from Merrimack College in N. Andover, Massachusetts with a BS in Medical Technology and completed her MS in Clinical Laboratory Sciences at the University of Massachusetts, Lowell. She has worked as a Medical Technologist for over 40 years and has taught as an adjunct faculty member at Merrimack College, UMass Lowell and Stevenson University for over 20 years.  She has worked in all areas of the clinical laboratory, but has a special interest in Hematology and Blood Banking. She currently works at Mercy Medical Center in Baltimore, Md. When she’s not busy being a mad scientist, she can be found outside riding her bicycle.

AIDS/HIV, the LGBTQ Community, and PRIDE Month: A Reflection

This reflection is dedicated with gratitude to the many LGBTQ activists who courageously engaged with politicians, scientists, and health leaders to advance the care of patients worldwide.

Forty years ago this month, near the end of my second year in Pathology Residency, Morbidity and Mortality Weekly Report reported a small case series in its June 5, 1981 issue describing Pneumocystis pneumonia in 5 homosexual men. Soon there were additional reports of gay men affected by P. carinii (now renamed P. jiroveci) pneumonia, Kaposi sarcoma, and other unusual opportunistic infections. These riveting descriptions signaled a new disease entity, soon known as Acquired Immunodeficiency Syndrome (AIDS). Initially some labeled AIDS “the gay disease” or “the gay cancer,” and the fear and stigma associated with AIDS led to discrimination, including evictions from housing, threats of evictions of clinics that served AIDS patients, and fear among some people of even casual contact with people affected by the disease.

At that time, I was training in a tight-knit cohort of residents who studied and socialized together. In those days we performed autopsies in street clothes, with only plastic aprons and gloves as “protective gear”- no masks, no face shields or goggles, no scrub suits. Within a few months of the MMR report, after AIDS fatalities in our training hospital, many of us went to the Autopsy room to observe the unusual findings at our gross organ review rounds, which were same-day examinations of fresh tissue. The next year, in the summer of 1982, I was married in a small ceremony that included only family and a few of my parents’ closest friends. Several years later two men who attended my wedding died of AIDS, and two of my fellow residents, and their partners, also died of AIDS.

By December, 1982, AIDS had been reported in a baby who had received multiple blood transfusions, and in January, 1983, AIDS was documented in women who had been sexual partners of men with AIDS and in people injecting drugs. These reports dispelled the idea that AIDS was unique to the gay community and suggested that the disease was likely due to an infectious agent that could be transmitted through blood, blood products, and sexual contact. Then in my Fellowship, still performing many autopsies, I was amazed at the dramatic change in protocols that appeared nearly overnight, as we were now required to use personal protective equipment for any work involving blood and fresh tissues. We gowned, double-gloved, wore masks and face shields, scrubs, and shoe covers when performing autopsies; and we were trained more diligently in managing needles and scalpel blades, as well as safety in procedures.

Pathologists and laboratory professionals soon learned to identify opportunistic infections that previously had been extremely rare outside the setting of severe immunosuppression. Multiple concurrent opportunistic infections were so common that it became second nature to scan any microscopic tissue section for cytomegalovirus, toxoplasmosis, fungal infection, atypical Mycobacteria, Kaposi sarcoma, and other findings. I learned from firsthand experience that there may not always be a single unifying diagnosis, in the sense that an immunocompromised patient may suffer with multiple infectious agents. By 1987, as a young attending pathologist on weekend call, I had to learn to perform by hand special rapid Gomori methenamine silver stains on any cases that required them. (As case numbers increased, the service began to employ histotechnologists to cover the weekends.)

Discovery of the causative infectious agent, Human Immunodeficiency Virus (HIV), by groups led by Montagnier (1983) and by Gallo (1984), was a critical step for the development of an accurate serologic test (1985) to detect pre-symptomatic disease. Publication of the retroviral sequence later facilitated the development of treatments, such as AZT, which was approved in 1987, and later to Highly Active Antiretroviral Therapy (HAART) in 1997. The development of effective antiretroviral therapies along with accurate and sensitive laboratory tests for HIV offered the opportunity to test and treat asymptomatic people before they developed severe immunosuppression and opportunistic infections.  

This abbreviated summary greatly understates the devastating toll that the pandemic has wreaked and continues to wreak. Millions of young and middle-aged people across the globe, of all nationalities, in all communities, have died. Many children were orphaned. Those of my generation continue to mourn the losses of the people we loved and wonder in grief at the creativity and potential contributions also lost to our society and culture.

And, sadly, HIV rages on. Intravenous drug users and men who have sex with men continue to face discrimination and abuse in many countries. Access to preventive therapy and lifesaving (but not yet curative) antiretroviral treatment is still denied or unavailable to many patients. Efforts to develop an effective vaccine have been unsuccessful to date. Work to address the global nature of this pandemic have required international cooperation and coordinated efforts, that continue to this day. The current extensive global health activities of ASCP stem greatly from the Society’s early invitation to set up HIV testing for the PEPFAR (President’s Emergency Plan for AIDS Relief) effort, which has also led to engagement in laboratory quality improvement efforts and workforce training worldwide. Finally, as we honor our LGBTQ colleagues, patients, and family members during PRIDE month, it is important to acknowledge that members of LGBTQ Community have been at the forefront of health care advocacy since the HIV pandemic first emerged. The tremendous progress in treatment, testing, and global strategies are results of their continuing energy, initially in the U.S. and now around the world to help other communities. We are all indebted to HIV/AIDS activists, such as the Gay Men’s Health Crisis and ACT UP, who have engaged politically, staged public awareness-building efforts, and challenged political and health care leaders and research scientists to address the emergency posed by the infection. Their efforts led to greatly accelerated treatment trials and effective treatments, and they have fought to have drug costs lowered to increase access. They can take great PRIDE in their lasting contributions to help patients everywhere.

-Dr. Upton is board certified in Anatomic Pathology and Cytology and directed an autopsy service and forensic pathology fellowship program at Beth Israel Deaconess Medical Center in Boston, Massachusetts. She has also practiced cytopathology and general surgical pathology, and has focused on genitourinary pathology, head and neck pathology, and gastroenterology (GI) and liver pathology. From 1982-85 and 1987-2002, Dr. Upton lived in Boston and taught at Tufts, Boston, and Harvard Universities. Since 2002, she has been at the University of Washington in Seattle, where she formerly directed the GI and Hepatic Pathology Service the Pathology Residency Program and the UW GI and Hepatic Pathology Fellowship. Currently Emeritus Professor of Pathology, she continues to practice Surgical Pathology, Autopsy Pathology, and Cytopathology, and she is one of the specialists at UW in the areas of GI, liver, and pancreatic pathology.

The Great Mimicker

I’ve witnessed that radiologists are often hesitant to perform a core biopsy on a spleen due to its vascularity, so when I attend spleen FNAs, I rarely push. Even when the oncology team requests both a core biopsy and FNA for a hematology workup, I will acquire as many passes as possible from an FNA to work up cytomorphology and flow cytometry before risking a core-induced hemorrhagic complication. When I was called to attend an ultrasound-guided spleen biopsy, I went in knowing two things: the patient has both splenic and brain lesions, and I was going to make the most of what I was given. When I arrived in ultrasound, the radiologist informed me that the patient had polycythemia vera (PV), which would explain the splenomegaly, but not the brain lesions. The patient, a 65 year old male, received the diagnosis in 2009 and was managed with phlebotomies for six years until a rising platelet and white blood cell count required an intervention of hydroxyurea. Within 18 months, the patient developed a PE and dizziness and began therapeutic anticoagulation. At the same time, the patient’s “metastatic lesions” were identified on imaging. The first state of business is finding out if his PV had progressed into myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). There was something… off… about this case though. It didn’t feel like a heme case (not that I prefer non-heme cases… well, okay, I’m a cytotech, so I kind of do). The brain lesions concerned me, and I didn’t know what to infer.

Let’s progress to the FNA. Here are the air-dried, Diff-Quik smears that changed everything.

Images 1-2: Splenic mass, fine needle asperation, DQ-stained smears.

What non-heme surprise is THIS?! Are these histiocytes? There’s no way, those nucleoli are aggressive! Look at the chromocenters! The variation in nuclear size! What epithelial beauty is this? Is it epithelial?! Is that a fibrovascular core? It can’t be sarcomatoid, could it? Twenty inner monologue questions later, “okay, it’s adequate,” I said to the radiologist. But wait… should I do it? Should I press for a core biopsy? The radiologist asked me if I needed anything else for the diagnosis. Perhaps she saw my puzzled expression, compelling her to tell me that she felt the imaging looked weird – she thought it wasn’t a heme case either. At least I’m not alone here. I took a deep breath, expecting the worst and hoping for the best, and I asked the radiologist to collect a core biopsy. She checked the ultrasound Doppler for excessive vascularity, and much to my surprise, she agreed to perform the core. After collecting more FNAs for my cell block and dropping the core biopsies off in surgical pathology, I showed the case to my attending pathologist. He also agreed that we don’t need to triage it for heme. He asked if the patient had any significant history other than PV, splenic lesions, and brain mets, and I told him nothing was reported in his chart. I checked the chart again for good measure while he was running through his differential diagnoses of lung, GI, prostate, etc., and saw the patient was scheduled to see dermatology later that week. I mentioned to that to my attending, and he suggested it could be a melanoma.

The following morning, I examined the pap-stained slide and began to second guess myself. Was I wrong? Could it be a heme case? Hodgkin’s wasn’t in the differential, and these cells look so much more aggressive than Reed-Sternberg cells. At least we have a core biopsy either way. We could run immunos on the cell block and save the cores for molecular. I screened the pap-stained slides a little longer, focusing on the macronucleoli, the owl-eye and eccentric nuclei, the poorly-differentiated nature of this… MELANOMA. YES! So, the cells might not contain any melanin pigment, but my attending’s inkling was exactly right. Waiting for my cell block to arrive, I listed melanoma as my primary diagnosis with a differential of lung or prostate cancer.

Images 3-4: Splenic mass, fine needle aspiration, Pap-stained smear.

The cell block confirmed my non-heme diagnosis and kept my differentials at bay. The attending pathologist ordered an immunohistochemistry profile of S100, HMB-45, and Melan A, as well as AE1/AE3. The first three immunostains (prior to our adoption of SOX-10) confirmed a diagnosis of metastatic malignant melanoma. Soon thereafter, the patient’s primary lesion was identified on his back, and he was treated with radiation and immunotherapy. Unfortunately, the metastases were not responding to the immunotherapy, and a few days after a clinical trial was offered, the patient passed away.

Images 5-8: Splenic mass, fine needle aspiration. 5 and 6, cell block, H&E; 7 and 8, Melan A+.

Melanoma is known as the great mimicker, especially in amelanotic form, and it should always be in the back of your mind as a differential diagnosis. Lack of melanin pigment and a large cherry red macronucleoli leads us to favor lung, prostate, or serous adenocarcinoma), renal cell carcinoma, hepatocellular carcinoma, Hodgkin’s lymphoma, or even an epithelioid sarcoma. This case highlights the need to remember that metastatic melanoma is always a possibility, even when you do not have a primary site or previous clinical history of the disease.

-Taryn Waraksa, MS, SCT(ASCP)CM, CT(IAC), has worked as a cytotechnologist at Fox Chase Cancer Center, in Philadelphia, Pennsylvania, since earning her master’s degree from Thomas Jefferson University in 2014. She is an ASCP board-certified Specialist in Cytotechnology with an additional certification by the International Academy of Cytology (IAC). She is also a 2020 ASCP 40 Under Forty Honoree.

The ABCs For Designing Sustainable Public Health Initiatives: A Simple Framework For Program Planners

If there is anything the COVID-19 pandemic has taught us, it is the fact that the world is a global village with no country being completely immune from the effects of disease and pathogens. With migration across borders along with its attendant effects of disease dissemination, public health initiatives aimed at improving the health outcomes of populations must be designed with the target population in mind and long-term sustainability prioritized. The health of a community is dependent on the overall health of its people. Public health initiatives are often designed to modify health and disease patterns within groups of people. A key measure of success of any health initiative is its long-term sustainability. Therefore, a framework to guide program planners at the design stage of any public health program is critical to success. This framework can be summed up as the ABCs for designing sustainable public health initiatives.

Appraisal: Appraisal is defined as an act of assessing something or someone. It is an evaluation of a process, system, or population. An appraisal of any given situation or entity is carried out to give the full picture, without redundancy or superfluity. When a thorough appraisal is carried out, it elaborates the situation on the ground, and the best approaches to tackle any challenges. For an appraisal of a public health problem, the following key activities should be included in the program design.

  1. Root Cause Analysis: A Root Cause Analysis (RCA) is a term that describes techniques and tools used to uncover the causes of a problem or failure.1 A RCA is often carried out to get to the bottom of a problem, and not to only focus on the offshoot of the problem-the observable symptom. A thorough RCA defines the problem, answers all the ‘why’ questions, and proffers solutions that lend themselves to evaluations which address the problems.
  2. Social Determinants of health: What makes one community healthy, and the other unhealthy? What factors contribute to the well-being of communities? The social determinants of health are a consortium of factors apart from medical care that can be influenced by social policies and shape health in powerful ways.2 It is important to note that what may positively impact the health of one community, may negatively impact the health of another. Public health practitioners must be able to determine the most important influencers to health and diseases in any community, to potentiate the cost-effectiveness of any intervention. The social determinants of health can be summed up as the 3 G’s:
  3. Geography-The physical environment and all the elements of nature. These include access to clean drinking water, healthy food portions, climate change, global warming, etc.
  4. Goods-These includes the social and economic environment. People’s relationships, income levels, social status, education levels, etc.
  5. Genes-These includes a person’s genetic make-up, which has been shown to have a great impact on health and certain diseases.

Therefore, a thorough analysis and understanding by public health practitioners on the most important contributor to health, and targeting resources to such areas, will increase the likelihood of success of any health intervention or campaign.

  • Influence of Community Stakeholders: A stakeholder’s analysis is a process of systematically gathering and analyzing qualitative information to determine whose interests should be taken into account when developing and/or implementing a policy or program.3 The stakeholders in a process are actors (persons or organizations) with a vested interest in the policy or program being implemented.3 After conducting a stakeholder analysis of the key interest groups, it is imperative to determine the influence of community stakeholders on the proposed public health initiative. Community leaders have a great influence on their constituents. Therefore, the success or ultimate failure of a project depends in part on the role of these key community actors. Vital questions must be asked and answered including but not limited to: what is their interest in the project? What is their knowledge of the project? Do they have an adequate understanding of the major root causes of the problem? Do they proffer alternate ways to address the problem? What is their voting power in the decision-making process? These are some of the key factors that may be considered when trying to determine the influence of community stakeholders on the proposed health intervention.
  • The Role of health models on disease causation, interpretation, and outcomes: The role of the models of health on disease incidence and survival cannot be overlooked. At the crux of any public health problem is the answer to some ‘why’ questions. It is a well-known fact that models of health including the religious, biomedical, psychosomatic, humanistic, existential and transpersonal all have a role to play in disease incidence and survival to varying degrees.4 While one model may play a more significant role in one community, the same may not be the case in another community. For example, while infections and communicable diseases are still a huge burden in many developing countries5 due to environmental and biophysical concerns including limited access to immunizations, the same is not the case in developed countries. Developed countries tend to grapple more with chronic diseases6 such as obesity, diabetes, hypertension, cancers. It is therefore the responsibility of program planners to determine during the design stages of projects, the models with greater impacts on disease causation and outcome. This approach may increase the likelihood of success than the failure of the intervention.

Budget: A budget is a financial statement detailing the income and expenditure of an entity over a given period. Proper budgeting encompasses adequate planning, both for foreseeable and unforeseeable expenditures. A budget should also include the fixed assets and in-kind or monetary contributions of the program to the execution of any public health initiative. A comprehensive budget should take into account direct and indirect costs including but not limited to personnel costs, travel costs, equipment/supplies, consultants, printing/duplication costs, postage, staff training, rent, telephone expenses, heavy machinery, etc. A project with an insufficient budget would be more likely to encounter challenges that may pose as threats to its sustainability, than one which is adequately funded. Therefore, program planners must ensure that their budgets are sufficient enough to run through the entire lifecycle of the projects.

Community buy-in: It would be an effort in futility if after going through the planning and design phases of a project, you discover that a community is not interested in that line of intervention. This would amount to a humungous waste of time and valuable resources. Therefore, program planners must ensure during the design phase of any project, to get the community’s perspective on that particular line of program approach. This is imperative because apart from getting the community’s perspective on a particular proposal, they may also be able to provide valuable pieces of information that may enhance the sustainability of any project. Community buy-in works in tandem with the role of the community’s stakeholders. Successful programs are designed for the people and with the people. In summary, at the crux of any planned public health intervention is the issue of long-term sustainability. Program planners should become familiar with addressing fundamental elements of successful program interventions. A good place to start is ensuring

References

  1. https://www.tableau.com/learn/articles/root-cause-analysis
  2. Braveman P, Gottlieb L. The social determinants of health: it’s time to consider the causes of the causes. Public Health Rep. 2014;129 Suppl 2(Suppl 2):19-31. doi:10.1177/00333549141291S206
  3. https://www.who.int/workforcealliance/knowledge/toolkit/33.pdf
  4. Tamm ME. Models of health and disease. Br J Med Psychol. 1993;66 ( Pt 3):213-228. doi:10.1111/j.2044-8341.1993.tb01745.x
  5. Tadesse GA, Javed H, Thanh NLN, et al. Multi-Modal Diagnosis of Infectious Diseases in the Developing World. IEEE J Biomed Health Inform. 2020;24(7):2131-2141. doi:10.1109/JBHI.2019.2959839
  6. Silvaggi F, Eigenmann M, Scaratti C, et al. Employment and Chronic Diseases: Suggested Actions for The Implementation of Inclusive Policies for The Participation of People with Chronic Diseases in the Labour Market. Int J Environ Res Public Health. 2020;17(3):820. Published 2020 Jan 28. doi:10.3390/ijerph17030820

-Evi Abada, MD, MS is a Resident Physician in anatomic and clinical pathology at the Wayne State University School of Medicine/Detroit Medical Center in Michigan. She earned her Masters of Science in International Health Policy and Management from Brandeis University in Massachusetts, and is a global health advocate. Dr. Abada has been appointed to serve on the ASCP’s Resident’s Council and was named one of ASCP’S 40 under Forty honorees for the year 2020. You can follow her on twitter @EviAbadaMD.

Microbiology Case Study: An 80 Year Old Man with a Violaceous Leg Lesion

An 80 year old male with a PMH of myelodysplasia with progression to AML and neutropenic fever presented with severe leg pain and violaceous leg lesion spanning a large portion of the left medial thigh and knee. There was no reported trauma. A radiograph demonstrated significant gas/air tracking in the tissues of the left medial thigh. He was given vanc/zosyn/clinda and subsequently transferred to UVMMC for further evaluation. He underwent debridement in the OR and fluid was sent for culture. Primary Gram stain showed no neutrophils and few gram positive bacilli. The blood agar plate and leg lesion are shown below.

Image 1. Growth on blood ager plate (BAP).
Image 2. Patient’s leg lesion.

This organism was identified on MALDI-MS as Clostridium septicum, consistent with the spreading colonies with irregular margins on blood agar. Box-car GPB morphology was present on gram stain, and although subterminal spores can be an additional clue to the identify C. septicum, they were not seen in this particular case.

Important diagnostic features of Clostridium septicum in the microbiology lab include:

  • GPB with rare subterminal spores (Image 3)
  • Gray/white colonies with irregular margins, translucent, β-hemolytic
  • Can show swarming growth pattern in < 24 hours on Schaedler plate (Image 4)
    • This swarming phenomenon is due to the ability to differentiate into giant hyperflagellated swarm cells, which can participate in migrations across surfaces
    • Major changes in virulence characteristics during swarming are reported
  • Lecithinase negative
  • Lipase negative
  • Gelatinase positive
  • Maltose positive
  • Indole negative
  • Urease negative
Image 3. Subterminal spores seen on Gram stain.
Image 4a. Swarming.
Image 4b. Swarming.

C. septicum is classically associated with GI malignancies and perforations when isolated in blood cultures. While less common than C. perfringens, Clostridium septicum can also cause gas gangrene (as in this case) along with C. novyi, C. histolyticum, C. sporogenes, and C. bifermentans. Importantly, in cases of nontraumatic gas gangrene, C. perfringens is the most common cause and classically presents as a primary perineum or extremity infection following bacterial translocation from the gastrointestinal tract. Patients with immune suppression, specifically neutropenia, are at increased risk of spontaneous gas gangrene due to C. septicum and have a high mortality rate.

To remember the colony morphology of the different Clostridial spp, you can think:

  • While C. Septicum Swarms, C. Perfringens Perforates (aka makes a double zone in the agar).

Edited to add: C. septicum is the most common cause of nontraumatic gas gangrene.

References

  1. McPherson, R, and M Pincus. (2011). Henry’s Clinical Diagnosis and Management By Laboratory Methods (22nd Edition, pp. 1155-1184). Philadelphia, PA: Elsevier Saunders.
  2. Murray PR et al: Medical Microbiology. 8th ed. Philadelphia: Elsevier, 2016
  3. Macha, Kosmas & Giede-Jeppe, Antje & Lücking, Hannes & Coras, Roland & Huttner, Hagen & Held, Jürgen. (2016). Ischaemic stroke and Clostridium septicum sepsis and meningitis in a patient with occult colon carcinoma – a case report and review of the literature. BMC Neurology. 16. 10.1186/s12883-016-0755-4.
  4. Stevens DL, Aldape MJ, Bryant AE. Life-threatening clostridial infections. Anaerobe. 2012;18(2):254–259.
  5. Macfarlane S, Hopkins MJ, Macfarlane GT. Toxin synthesis and mucin breakdown are related to swarming phenomenon in Clostridium septicum. Infect Immun. 2001;69(2):1120-1126. doi:10.1128/IAI.69.2.1120-1126.2001

-Nicole Mendelson, MD is a 3rd year Anatomic and Clinical Pathology Resident at the University of Vermont Medical Center.

-Christi Wojewoda, MD, is the Director of Clinical Microbiology at the University of Vermont Medical Center and an Associate Professor at the University of Vermont.

Microbiology Case Study: A Fishy Situation

Case History

The microbiology laboratory received a tissue specimen from a male patient in his 60s. The tissue was biopsied from the patient’s hand during surgery at an outside hospital, but no further clinical information was available. No organisms were observed on the Gram stain, fungal smear, or fluorochrome stain and no white blood cells were observed on the Gram stain. No organisms were recovered from the aerobic or anaerobic bacterial culture or fungal culture.

After 20 days of acid-fast bacilli (AFB) culture, yellow colonies grew on the Lowenstein Jensen (LJ) media and the 7H10 media (Image 1) and acid-fast bacilli were noted on the Kinyoun stain prepared from the colonies (Image 2).

Image 1. Yellow colonies on the 7H10 media.
Image 2. Kinyoun stain of the colonies demonstrating acid-fast bacilli. This is characteristic of Mycobacteria spp. Species-level identification is not possible based on morphology alone.

The ordering physician was contacted regarding the positive Kinyoun stain. Upon hearing that acid-fast bacilli grew in culture, the physician shared that he has a high suspicion for Mycobacterium marinum as this patient developed a wound infection after he cut his hand with a fish bone while cooking. MALDI-TOF identified this organism as Mycobacterium marinum, confirming the astute physician’s hypothesis. 

Mycobacterium marinum

Mycobacterium marinum is a slow growing non-tuberculous mycobacterium (NTM) that causes skin and soft tissue infections. M. marinum can be found in both fresh and saltwater environments and is commonly associated with contact with fish, fish tanks, marine shells, and non-chlorinated swimming pools, earning the names “swimming pool granuloma” and “fish tank granuloma.” Infections are normally localized to the skin and occur following trauma, with the limbs and extremities most often infected. Nodules or ulcers around the site of inoculation are most common—these are typically single nodules or ulcers but may spread along the lymphatic vessels to regional lymph nodes, similar to sporotrichosis. Rare manifestations of M. marinum include osteomyelitis and disseminated disease, with non-cutaneous manifestations occurring predominately in immunocompromised populations. M. marinum is a slowly progressing disease and the patient may not present to their provider until months after the initial trauma, often complicating the link to water or fish exposures. M. marinum, while it can be transmitted from fish to human, is not transmitted person-to-person and thus does not pose an infection control risk.

AFB cultures are typically incubated at 37 degrees C. However, M. marinum grows optimally at 30C with scant or no growth at 37degrees C. Thus, when skin and soft tissue samples are received for AFB culture, specimens should be held at both 37 degrees C and 30 degrees C to support growth of most NTM and to facilitate the growth of M. marinum, respectively. Recovery of M. marinum in culture from primary specimen takes several weeks to grow, but subculture may take less than 7 days.

M. marinum can be identified by phenotypic characterization, molecular identification, or mass spectrometry. M. marinum is a photochromogen, meaning that colonies possess a yellow pigment when grown in light and no pigment when grown in the dark. This is characteristic of group I of Runyon’s classification. Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF), which has been used for years in most clinical microbiology laboratories for the identification of bacteria and yeast, can be used to identify Mycobacteria to the complex or species level. While the processing of Mycobacteria for MALDI-TOF is more laborious than for bacterial identification, the use of MALDI-TOF for identification of Mycobacteria is increasing in use. Whole genome sequencing can be performed on pure isolates for molecular identification, although this is more expensive and less common than MALDI-TOF or phenotypic identification.

A thorough history identifying risk factors for M. marinum should be conducted by the physician. Given the length of time for growth, clinical suspicion due to water or fish exposures can guide treatment before the organism grows in culture.  In addition to providing a diagnosis and guiding clinical care, a history of M. marinum infection is also critical to note for latent tuberculosis screening as M. marinum can cross react with tuberculin skin testing and interferon gamma release assays.

References

  1. Aubry A, Mougari F, Reibel F, Cambau E. Mycobacterium marinum. Microbiol Spectr. 2017 Apr;5(2). doi: 10.1128/microbiolspec.TNMI7-0038-2016. PMID: 28387180.
  2. Wu TS, Chiu CH, Yang CH, Leu HS, Huang CT, Chen YC, Wu TL, Chang PY, Su LH, Kuo AJ, Chia JH, Lu CC, Lai HC. Fish tank granuloma caused by Mycobacterium marinum. PLoS One. 2012;7(7):e41296. doi: 10.1371/journal.pone.0041296. Epub 2012 Jul 20. PMID: 22911774; PMCID: PMC3401166.
  3. Franco-Paredes C, Marcos LA, Henao-Martínez AF, Rodríguez-Morales AJ, Villamil-Gómez WE, Gotuzzo E, Bonifaz A. Cutaneous Mycobacterial Infections. Clin Microbiol Rev. 2018 Nov 14;32(1):e00069-18. doi: 10.1128/CMR.00069-18. PMID: 30429139; PMCID: PMC6302357.

Paige M.K. Larkin, PhD, D(ABMM), M(ASCP)CM is the Director of Molecular Microbiology and Associate Director of Clinical Microbiology at NorthShore University HealthSystem in Evanston, IL. Her interests include mycology, mycobacteriology, point-of-care testing, and molecular diagnostics, especially next generation sequencing.

Microbiology Case Study: A 59 Year Old Male with Acute Prostatitis

Clinical history

A 59 year old male with a past medical history of benign prostatic hypertrophy who presented to his primary care physician with complaints of dysuria, urgency, nocturia, and a weak stream. He was referred to a urologist who diagnosed him with acute prostatitis. The patient was given Flomax, a medication that relaxes the muscles in the prostate and bladder, and sulfamethoxazole-trimethoprim, an antibiotic for his possible bladder infection. The patient continued to have urinary symptoms despite antibiotics and multiple urinary cultures that were negative for growth of bacteria. Eventually the patient’s symptoms worsened and he presented to the emergency department with symptoms of fever (102.8ºF), bladder spasms, drenching night sweats, and painful urinary retention. His lab results showed a mild leukocytosis (15,500 cells /mm3) and increased leukocyte esterase, leukocytes, and erythrocytes in his urine. He was admitted and a pelvic computed tomography scan showed multiple prostatic abscesses. The infectious disease team ordered a urine fungal culture. The fungal stain showed broad-budding yeast forms (Image 1).

Image 1. Calcofluor white fungal stain highlighting brad-based budding yeast (100x oil immersion).

Laboratory identification

A cytospin Gram stain was made of the urine specimen which showed rare large yeast forms, numerous red blood cells and neutrophils (Image 2). These yeast forms are consistent with Blastomyces dermatitidis which are 10-15 µm in diameter and have thick contoured cell walls. The fungal culture grew a dirty white leathery mold on inhibitory mold agar after ten days. The lactophenol cotton blue adhesive tape preparation highlighted short to long conidiophores with large pear-shaped conidia at the tips of delicate conidiophores and septated hyphae. A positive urine antigen test supports the identification of the organism as Blastomyces dermatitidis.

Image 2. Large yeast with thick refractile walls seen on Gram stain. Flattened areas suggest recent separation.

Discussion

Blastomyces dermatitidis is a dimorphic fungus commonly found in the eastern half of the United States and Canada, specifically the Mississippi and Ohio River valleys, and Great Lakes Region. It typically grows as a mold in damp soil and decomposing vegetation; outdoor activities that disrupt the soil can increase the risk of infection. Infection occurs when the reproductive spores known as conidia are inhaled into the alveoli of the lungs. There the conidia transform into yeast and multiply causing the disease blastomycosis. Approximately 50% of those infected with Blastomyces are asymptomatic and clear the infection without trouble. For the other 50%, symptoms depend on the course of infection with a range of flu-like illness over a few days to chronic or severe illness that can last for months. Symptoms include fever, chills, headache, joint and muscle pains, shortness of breath, cough, night sweats, weight loss, and pleuritic chest pain. Twenty to forty percent of symptomatic patients will have disseminated disease. The common extra-pulmonary sites include skin, bone, urogenital, and the central nervous system, however, it has been reported in all organ systems.

In our case, the patient presented with prostatic blastomycosis which was quickly identified by calcofluor white fungal stain and urine antigen test. The patient was placed on itraconazole and a transurethral prostatic resection was performed. Histopathologic analysis showed necrotizing granulomas with fungal elements that are consistent with Blastomyces dermatitidis (Image 3). After a few days of treatment, the patient was discharged and is being followed on an outpatient basis.

Image 3. PAS stained tissue showing three budding yeast forms in a granuloma with extensive neutrophilic reaction.

– Joshua Wodskow, DO is a 1st year clinical and anatomic pathology resident at University of Chicago (NorthShore). Academically, Joshua has a particular interest in hematopathology and informatics. In his spare time, Joshua enjoys board games with his family and listening to podcasts.

-Erin McElvania, PhD, D(ABMM), is the Director of Clinical Microbiology NorthShore University Health System in Evanston, Illinois. Follow Dr. McElvania on twitter @E-McElvania. 

The More Things Change: 3 Ways to Determine Lab Safety Culture

On which side of the aisle do you stand regarding the subject of change? Things change, or things never change? The only constant is change, or it’s always the same old thing? When it comes to the laboratory safety culture, there are some generally-accepted thoughts; change is difficult, change is slow, and change takes persistence and patience.

I’ve heard other things too- people hate change, or people like change as long as they get to be in charge of it. I do believe most of us like change. After all, we change our clothes, we re-arrange our furniture, we remodel a room in our home. It can be exciting, but the tables seem to turn if it’s a change that is forced upon us or that was not our decision (Think about all of the changes the pandemic forced upon us last year!). Changing your lab safety culture for the better can be difficult, but it can be done. First, however, you need to know the current culture and goings-on in your lab in order to be able to make a difference.

There are specific ways to determine the safety culture in your lab. An experienced safety professional can do it fairly quickly. For others, especially those who serve in multiple capacities (you know who you are- you’re in charge of lab safety but you’re also the lab manager, or the quality coordinator, or the POCT coordinator) – for you assessing the culture can be difficult, even with years of experience- because you have so many other things on your plate. That can hinder your ability to make quick assessments, but it will not hinder you completely from being able to make a true safety assessment.

To make an assessment you need to use three specific tools that you likely have at your disposal. These tools may come in a variety of forms.

Those who have followed my work for some time know about the tool “Safety Eyes.” This is a safety assessment tool I believe to be a “superpower” that we all have and need to develop. It is so powerful, in fact, that a developed user can make a fairly good and accurate safety assessment with a quick glance into the department. Performing a lab safety audit is also a very valuable tool that can give you much information about the department’s culture. Perform a complete audit at least annually, and follow-up on the results. Otherwise, you have wasted your time and resources.

A second important safety culture gauge is the use of a written or electronic safety culture assessment. You may be able to tell what’s going on visually and physically by the evidence of your eyes and safety audits, but this tool is a way to actually get into the heads of your staff. What do they think of the culture? What is their opinion of it? What do they think needs improvement, and how would they suggest making those changes? A safety culture assessment can be given to everyone, or it can be used for specific lab groups. Survey the lab staff, survey those responsible for safety, or survey lab leadership. You should perform a lab safety culture assessment at least annually, but it can be done more often as needed.

Lastly, you can use laboratory data that you already collect to see the current state of safety in the department. Analyzing the data you collect about the injuries, accidents and exposures in your laboratory can be very eye-opening, and if you share the data as safety education, you may be able to lower the number of these types of incidents. Look at the chemical and biological spills in the lab. Analyze how they happened and how to prevent a re-occurrence. If you’re the quality coordinator for your lab or system, you know about root cause and common cause analyses. The incidents that occur in the lab that generate a root cause investigation may not always be about lab safety, but it’s possible that investigations show safety is a key factor, and those results should be reviewed with the safety person in the lab.

There is much fact-gathering in the laboratory setting, even regarding the topic of safety. However, all of that data becomes worthless if there is no action taken with it. Audits, injury data, spill information – it can be very valuable information and it can all be used as tools to help you truly change your lab safety culture. If you use them properly, you can make a change, you can make a difference, and you might just end up on the correct side of the change aisle!

Dan Scungio, MT(ASCP), SLS, CQA (ASQ) has over 25 years experience as a certified medical technologist. Today he is the Laboratory Safety Officer for Sentara Healthcare, a system of seven hospitals and over 20 laboratories and draw sites in the Tidewater area of Virginia. He is also known as Dan the Lab Safety Man, a lab safety consultant, educator, and trainer.